Myriad Genetics Inc: (NASD: MYGN)

$33.01

-0.05 (-0.15%)

Volume 892,015

May 21 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Detailed Estimates

Current Quarter Estimate	0.43
Next Quarter Estimate	0.43
Current Year Estimate	1.66
Next Year Estimate	1.86
Expected Earnings Growth	12.62%
Expected Sales Growth	10.24%
Next Earnings Report Date	08-13-2013
EPS Last Quarter	0.39
Last Quarter EPS Surprise	17.95%
EPS (Trailing 12 Mos.)	1.58
PE (Forward)	19.86
ABR	2.18

Learn More About Estimate Research

See Brokerage Recommendations

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

            Premium research: Industry Analysis
        
		Top Peers
		Symbol
		Zacks Rank
	
		MYRIAD GENETICS
		MYGN
		
		AETERNA ZENTARS
		AEZS
		
		ANIKA THERAPEUT
		ANIK
		
		GENTIUM SPA-ADR
		GENT
		
		AASTROM BIOSCI
		ASTM
		
		ACHILLION PHARM
		ACHN
		
		ADDEX THERA LTD
		ADDXF
		
		AFFYMAX INC
		AFFY
		
		ALEXION PHARMA
		ALXN
		
		ALKERMES INC
		ALKS
		
                                  See all MED-BIOMED/GENE Peers
                                
Turn Earnings Surprises into quick profits.

Top Peers	Symbol	Zacks Rank
MYRIAD GENETICS	MYGN
AETERNA ZENTARS	AEZS
ANIKA THERAPEUT	ANIK
GENTIUM SPA-ADR	GENT
AASTROM BIOSCI	ASTM
ACHILLION PHARM	ACHN
ADDEX THERA LTD	ADDXF
AFFYMAX INC	AFFY
ALEXION PHARMA	ALXN
ALKERMES INC	ALKS

            Earnings Growth Estimates
         
		MYGN
		IND
		S&P
	
		Current Qtr (06/2013)
		25.82
		NA
		NA
	
		Next Qtr (09/2013)
		18.75
		NA
		NA
	
		Current Year (06/2012)
		28.10
		5.40
		11.40
	
		Next Year (06/2013)
		11.70
		15.60
		6.50
	
		Past 5 Years
		NA
		17.80
		5.70
	
		Next 5 Years
		12.60
		16.90
		NA
	
		PE
		19.90
		-5.90
		15.50
	
		PEG Ratio
		1.57
		-0.35
		NA
	
            Detailed Earnings Estimates
         
		Current Qtr 
 (06/2013)
		Next Qtr 
 (09/2013)
		Current Year 
 (06/2013)
		Next Year 
 (06/2014)
	
		Zacks Consensus Estimate
		0.43
		0.43
		1.66
		1.86
	
		# of Estimates
		9
		4
		8
		8
	
		Most Recent Consensus
		0.43
		0.45
		1.66
		1.91
	
		High Estimate
		0.45
		0.45
		1.68
		2.00
	
		Low Estimate
		0.40
		0.37
		1.65
		1.60
	
		Year ago EPS
		0.34
		0.36
		1.30
		1.66
	
		Year over Year Growth Est.
		25.82%
		18.75%
		28.08%
		11.71%
	
            Agreement - Estimate Revisions
       
		Current Qtr 
(06/2013)
		Next Qtr  
(09/2013)
		Current Year 
 (06/2013)
		Next Year 
   (06/2014)
	
		Up Last 7 Days
		0
		0
		0
		0
	
		Up Last 30 Days
		6
		2
		6
		7
	
		Up Last 60 Days
		6
		2
		3
		7
	
		Down Last 7 Days
		0
		0
		0
		0
	
		Down Last 30 Days
		0
		0
		0
		0
	
		Down Last 60 Days
		0
		0
		0
		0
	
            Magnitude - Consensus Estimate Trend
       
		Current Qtr 
 (06/2013)
		Next Qtr 
 (09/2013)
		Current Year 
 (06/2013)
		Next Year 
 (06/2014)
	
		Current
		0.43
		0.43
		1.66
		1.86
	
		7 Days Ago
		0.43
		0.43
		1.66
		1.86
	
		30 Days Ago
		0.41
		0.41
		1.58
		1.78
	
		60 Days Ago
		0.41
		0.41
		1.57
		1.78
	
		90 Days Ago
		0.41
		0.41
		1.58
		1.78
	
            Upside - Most Accurate Estimate versus Zacks Consensus
         
		Current Qtr 
 (06/2013)
		Next Qtr 
 (09/2013)
		Current Year 
 (06/2013)
		Next Year 
 (06/2014)
	
		Most Accurate Estimate
		0.43
		0.45
		1.66
		1.90
	
		Zacks Consensus Estimate
		0.43
		0.43
		1.66
		1.86
	
		Earnings ESP 
		0.00%
		4.65%
		0.00%
		2.15%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus. This % difference = the expected surprise prediction.

            Surprise - Reported Earnings History
         
		Quarter Ending 
 (03/2013)
		Quarter Ending 
 (12/2012)
		Quarter Ending 
 (09/2012)
		Quarter Ending 
 (06/2012)
		Average Surprise
	
		Reported
		0.46
		0.42
		0.36
		0.34
		NA
	
		Estimate
		0.39
		0.38
		0.32
		0.34
		NA
	
		Difference
		0.07
		0.04
		0.04
		0.00
		0.05
	
		Surprise
		17.95%
		10.53%
		12.50%
		0.00%
		13.66%
	
        Earnings Transcript for MYGN from 11/05/2012
        
                                Quarterly Estimates by Analyst
                            
                                Zacks Premium Subscription Required Learn more
                            
                                Annual Estimates by Analyst
                            
                                Zacks Premium Subscription Required Learn more

Username: Password:

Remember me [?]

Forgot Password

New Member

Myriad Genetics Inc: (NASD: MYGN)

$33.01

-0.05 (-0.15%)

Volume 892,015

May 21 04:00 PM ET

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Zacks Industry Rank

Equity Research Report

Premium research: Industry Analysis

See all MED-BIOMED/GENE Peers

Earnings Growth Estimates

Detailed Earnings Estimates

Agreement - Estimate Revisions

Magnitude - Consensus Estimate Trend

Upside - Most Accurate Estimate versus Zacks Consensus

Surprise - Reported Earnings History

Quarterly Estimates by Analyst

Annual Estimates by Analyst

	MYGN	IND	S&P
Current Qtr (06/2013)	25.82	NA	NA
Next Qtr (09/2013)	18.75	NA	NA
Current Year (06/2012)	28.10	5.40	11.40
Next Year (06/2013)	11.70	15.60	6.50
Past 5 Years	NA	17.80	5.70
Next 5 Years	12.60	16.90	NA
PE	19.90	-5.90	15.50
PEG Ratio	1.57	-0.35	NA

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Zacks Consensus Estimate	0.43	0.43	1.66	1.86
# of Estimates	9	4	8	8
Most Recent Consensus	0.43	0.45	1.66	1.91
High Estimate	0.45	0.45	1.68	2.00
Low Estimate	0.40	0.37	1.65	1.60
Year ago EPS	0.34	0.36	1.30	1.66
Year over Year Growth Est.	25.82%	18.75%	28.08%	11.71%

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Up Last 7 Days	0	0	0	0
Up Last 30 Days	6	2	6	7
Up Last 60 Days	6	2	3	7
Down Last 7 Days	0	0	0	0
Down Last 30 Days	0	0	0	0
Down Last 60 Days	0	0	0	0

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Current	0.43	0.43	1.66	1.86
7 Days Ago	0.43	0.43	1.66	1.86
30 Days Ago	0.41	0.41	1.58	1.78
60 Days Ago	0.41	0.41	1.57	1.78
90 Days Ago	0.41	0.41	1.58	1.78

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Most Accurate Estimate	0.43	0.45	1.66	1.90
Zacks Consensus Estimate	0.43	0.43	1.66	1.86
Earnings ESP	0.00%	4.65%	0.00%	2.15%

	Quarter Ending (03/2013)	Quarter Ending (12/2012)	Quarter Ending (09/2012)	Quarter Ending (06/2012)	Average Surprise
Reported	0.46	0.42	0.36	0.34	NA
Estimate	0.39	0.38	0.32	0.34	NA
Difference	0.07	0.04	0.04	0.00	0.05
Surprise	17.95%	10.53%	12.50%	0.00%	13.66%